

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Zhaoke Ophthalmology Limited
兆科眼科有限公司

(Incorporated in the British Virgin Islands with limited liability and continued in the Cayman Islands)
(Stock Code: 6622)

**VOLUNTARY ANNOUNCEMENT – FIRST PATIENT ENROLLED
IN PHASE II CLINICAL TRIAL OF ZKY001 FOR TPRK**

This announcement is made by the board of directors (the “**Board**”) of Zhaoke Ophthalmology Limited (the “**Company**”) on a voluntary basis.

The Board of the Company is pleased to announce that the first patient was enrolled in the Phase II clinical trial of one of the Company’s drug candidates, ZKY001 for the indication of transepithelial photorefractive keratectomy (“**TPRK**”, surgical treatment for myopia), on August 5, 2022.

The Phase II clinical trial is a multi-center, randomized, double-blinded and placebo-controlled study. The main objective of the trial is to evaluate the efficacy and safety of ZKY001 in the treatment of corneal epithelial defects after TPRK, and to determine the dosage of ZKY001 in Phase III clinical trial. Led by Professor Zhou Xing Tao from Eye and ENT Hospital of Fudan University, the trial will involve 12 centers and enroll a total of 120 patients.

ABOUT ZKY001

ZKY001 is a seven-amino acid peptide derived from the functional fragment of Thymosin β 4 that binds actin, a type of protein that plays a central role in cell structure and movement. In addition to the Company’s leading Phase III innovative asset Cyclosporine A Ophthalmic Gel for dry eye, ZKY001 is another in-house developed program by the Company that is currently in clinical stage.

ZKY001 has broad applications in corneal wound healing and can potentially be used in multiple corneal repair indications. In addition to the Phase II clinical study for corneal epithelium repair after endothelial keratoplasty, the Company is currently exploring three additional indications for ZKY001, including TPRK (surgical treatment for myopia), pterygium (an outgrowth in the cornea or conjunctiva) and neurotrophic keratitis (a rare degenerative corneal disease).

Cautionary Statement required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: The Company cannot guarantee that it will ultimately develop and market ZKY001 successfully. Shareholders of the Company and potential investors are advised to exercise caution when dealing with the shares of the Company.

By order of the Board
Zhaoke Ophthalmology Limited
Dr. Li Xiaoyi
Chairman

Hong Kong, August 10, 2022

As at the date of this announcement, the Board of the Company comprises Dr. Li Xiaoyi and Mr. Dai Xiangrong as executive Directors; Ms. Leelalertsuphakun Wanee, Ms. Tiantian Zhang, Ms. Cai Li and Mr. Chen Yu as non-executive Directors; and Mr. Wong Hin Wing, Prof. Lo Yuk Lam and Mr. Liew Fui Kiang as independent non-executive Directors.